Avata

Avata Biosciences Ltd, formerly known as Sapient Therapeutics, is a privately held biopharmaceutical company with the mission of improving the lives of patients with neurological disorders. The company’s lead asset has successfully completed Phase 1 clinical trials and is set to enter the next phase of clinical development in 2024. Avata, led by a team of seasoned professionals in neuroscience and cannabinoid drug development, is leveraging its experience in cannabinoid therapeutics to bring new prescription medicines to patients suffering from serious conditions.